LH92

LH92 is a novel synthetic analogue of piperlongumine (PL), a plant-derived alkaloid with known anti-cancer properties. Developed by researchers at the University of Nottingham, LH92 is designed to target the glutathione (GSH) system, a major cellular redox buffering system that regulates the radioresponse of cancer cells and is often overexpressed in resistant tumors. In preclinical studies, LH92 has demonstrated potent cytotoxic effects, inhibiting cell proliferation and decreasing clonogenic survival in both triple-negative breast cancer (TNBC) and luminal breast cancer cell lines. Unlike some other piperlongumine analogues, LH92 shows differential sensitivity in clonogenic assays, with TNBC cells being significantly more sensitive to its cytotoxic effects compared to luminal breast cancer cells.